Evidence map›Paper›PMID 33988313›Full record

ArticleESC heart failure2021

Involvement of chronic inflammation via monocyte chemoattractant protein-1 in uraemic cardiomyopathy: a human biopsy study.

Tomoya Nakano, Kenji Onoue, Ayako Seno, Satomi Ishihara, Yasuki Nakada, Hitoshi Nakagawa, Tomoya Ueda, Taku Nishida, Tsunenari Soeda, Makoto Watanabe and 5 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. sFlt-1 in Chronic Kidney Disease: Friend or Foe?International journal of molecular sciences · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Tomoya NakanoDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0001-7459-3070
Kenji OnoueDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0003-3233-4913
Ayako SenoDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Satomi IshiharaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Yasuki NakadaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0003-0510-6923
Hitoshi NakagawaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Tomoya UedaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Taku NishidaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0001-7025-0310
Tsunenari SoedaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0001-5386-584X
Makoto WatanabeDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Rika KawakamiDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Kinta HatakeyamaDepartment of Pathology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.ORCID 0000-0001-7729-1836
Yasuhiro SakaguchiDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Chiho OhbayashiDepartment of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0002-8046-9508
Yoshihiko SaitoDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.ORCID 0000-0001-5574-3571
Nara Medical University · JPNational Cerebral and Cardiovascular Center · JPYamato Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPatients undergoing dialysis, even those without coronary artery disease or valvular abnormalities, sometimes present with reduced heart function, which resembles dilated cardiomyopathy (DCM). This condition is known as uraemic cardiomyopathy (UCM). The mechanisms of UCM development are not fully understood. Previous studies demonstrated that the balance between placental growth factor (PlGF) and fms-like tyrosine kinase-1 (Flt-1) is correlated with renal function, and PlGF/Flt-1 signalling is involved in the development of cardiovascular diseases in patients with chronic kidney disease. This study was conducted to evaluate the pathogenesis of UCM and clarify the differences in the mechanisms of UCM and DCM by using human endomyocardial biopsy and blood samples. METHODS AND

resultsThe clinical and pathological features of 30 patients on dialysis with reduced cardiac function [left ventricular ejection fraction (LVEF) ≤50%] (UCM group; mean age: 58.5 ± 9.4 years and LVEF: 39.1 ± 7.2%), 196 DCM patients (DCM group; mean age: 62.7 ± 14.0 years and LVEF: 33.5 ± 8.8%) as controls with reduced cardiac function (LVEF ≤ 45%), and 21 patients as controls with normal cardiac function (control group; mean age: 56.2 ± 19.3 years and LVEF: 67.5 ± 6.7%) were analysed. The percentage of the interstitial fibrosis area in the UCM group was greater than that in the DCM group (P = 0.045). In UCM patients, the percentage of the interstitial fibrosis area was positively correlated with the duration of renal replacement therapy (P < 0.001). The number of infiltrated CD68-positive macrophages in the myocardium and expression of monocyte chemoattractant protein-1 (MCP-1) in cardiomyocytes were significantly greater in the UCM group than in the other groups (P < 0.001, respectively). Furthermore, while the serum level of soluble form of Flt-1, an endogenous inhibitor of PlGF, in the UCM group was lower compared with that in the DCM group (P < 0.001), the serum levels of PlGF and PlGF/soluble form of Flt-1 ratio and plasma level of MCP-1 in the UCM group were higher than those in the DCM group (P < 0.001, respectively).

conclusionsThese results suggest that activated PlGF/Flt-1 signalling and subsequent macrophage-mediated chronic non-infectious inflammation via MCP-1 in the myocardium are involved in the pathogenesis of UCM.

Indexed as

CardiomyopathiesChemokine CCL2AdultAgedBiopsyFemaleHumansInflammationMiddle AgedPlacenta Growth FactorStroke VolumeVentricular Function, LeftCCL2 protein, humanChemokine CCL2Placenta Growth FactorHuman heart tissueImmunohistochemistryMonocyte chemoattractant protein-1Placental growth factorUraemic cardiomyopathy

Identifiers

PMID33988313
PMCPMC8318461
OpenAlexW3160453508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.